These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 32144686)
1. New developments in the management of achondroplasia. Högler W; Ward LM Wien Med Wochenschr; 2020 Apr; 170(5-6):104-111. PubMed ID: 32144686 [TBL] [Abstract][Full Text] [Related]
2. Maternal administration of meclozine for the treatment of foramen magnum stenosis in transgenic mice with achondroplasia. Matsushita M; Mishima K; Esaki R; Ishiguro N; Ohno K; Kitoh H J Neurosurg Pediatr; 2017 Jan; 19(1):91-95. PubMed ID: 27767902 [TBL] [Abstract][Full Text] [Related]
4. Disease-specific complications and multidisciplinary interventions in achondroplasia. Kitoh H; Matsushita M; Mishima K; Kamiya Y; Sawamura K J Bone Miner Metab; 2022 Mar; 40(2):189-195. PubMed ID: 35028714 [TBL] [Abstract][Full Text] [Related]
5. [Clinical features and Zhang HQ; Tao DY; Zhang JJ; Niu HH; Luo JF; Cheng SQ Zhongguo Dang Dai Er Ke Za Zhi; 2022 Apr; 24(4):405-410. PubMed ID: 35527416 [TBL] [Abstract][Full Text] [Related]
6. Promising horizons in achondroplasia along with the development of new drugs. Ozono K; Kubota T; Michigami T Endocr J; 2024 Jul; 71(7):643-650. PubMed ID: 38569854 [TBL] [Abstract][Full Text] [Related]
8. Achondroplasia: Current Options and Future Perspective. Bouali H; Latrech H Pediatr Endocrinol Rev; 2015 Jun; 12(4):388-95. PubMed ID: 26182483 [TBL] [Abstract][Full Text] [Related]
9. Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype. Murakami S; Balmes G; McKinney S; Zhang Z; Givol D; de Crombrugghe B Genes Dev; 2004 Feb; 18(3):290-305. PubMed ID: 14871928 [TBL] [Abstract][Full Text] [Related]
10. European Achondroplasia Forum guiding principles for the detection and management of foramen magnum stenosis. Irving M; AlSayed M; Arundel P; Baujat G; Ben-Omran T; Boero S; Cormier-Daire V; Fredwall S; Guillen-Navarro E; Hoyer-Kuhn H; Kunkel P; Lampe C; Maghnie M; Mohnike K; Mortier G; Sousa SB Orphanet J Rare Dis; 2023 Jul; 18(1):219. PubMed ID: 37501185 [TBL] [Abstract][Full Text] [Related]
11. Advantages and Disadvantages of Different Treatment Methods in Achondroplasia: A Review. Wrobel W; Pach E; Ben-Skowronek I Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070375 [TBL] [Abstract][Full Text] [Related]
12. [New treatments for achondroplasia may be efficacious in other forms of short stature]. Nilsson O Lakartidningen; 2021 Feb; 118():. PubMed ID: 33647161 [TBL] [Abstract][Full Text] [Related]
13. Rationale, design, and methods of a randomized, controlled, open-label clinical trial with open-label extension to investigate the safety of vosoritide in infants, and young children with achondroplasia at risk of requiring cervicomedullary decompression surgery. Savarirayan R; Irving M; Maixner W; Thompson D; Offiah AC; Connolly DJ; Raghavan A; Powell J; Kronhardt M; Jeha G; Ghani S; Fisheleva E; Day JR Sci Prog; 2021; 104(1):368504211003782. PubMed ID: 33761804 [TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor receptor-3 as a therapeutic target for Achondroplasia--genetic short limbed dwarfism. Aviezer D; Golembo M; Yayon A Curr Drug Targets; 2003 Jul; 4(5):353-65. PubMed ID: 12816345 [TBL] [Abstract][Full Text] [Related]
16. Delayed bone age due to a dual effect of FGFR3 mutation in Achondroplasia. Pannier S; Mugniery E; Jonquoy A; Benoist-Lasselin C; Odent T; Jais JP; Munnich A; Legeai-Mallet L Bone; 2010 Nov; 47(5):905-15. PubMed ID: 20673820 [TBL] [Abstract][Full Text] [Related]
17. Lifetime impact of achondroplasia: Current evidence and perspectives on the natural history. Hoover-Fong J; Cheung MS; Fano V; Hagenas L; Hecht JT; Ireland P; Irving M; Mohnike K; Offiah AC; Okenfuss E; Ozono K; Raggio C; Tofts L; Kelly D; Shediac R; Pan W; Savarirayan R Bone; 2021 May; 146():115872. PubMed ID: 33545406 [TBL] [Abstract][Full Text] [Related]
18. Emerging therapies for Achondroplasia: changing the rules of the game. Kumble S; Savarirayan R Expert Opin Emerg Drugs; 2021 Dec; 26(4):425-431. PubMed ID: 34758681 [TBL] [Abstract][Full Text] [Related]
19. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. Webster MK; Donoghue DJ EMBO J; 1996 Feb; 15(3):520-7. PubMed ID: 8599935 [TBL] [Abstract][Full Text] [Related]
20. Shedding New Light: Novel Therapies for Achondroplasia and Growth Disorders. Merchant N; Dauber A Pediatr Clin North Am; 2023 Oct; 70(5):951-961. PubMed ID: 37704353 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]